Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.
Charles Dadswell, senior vice president and general counsel, has been named interim CEO, while the board conducts a search for a new CEO. Illumina said deSouza, who has been with the company since 2013 and was named CEO three years later, will stay on in an advisory capacity until July 31.
“Illumina’s technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry,” Illumina's board chair, Stephen P. MacMillan, said in a statement. “We are confident Illumina can continue to execute on its goals, while we conduct and complete a CEO search process.”
The company, based in San Diego, said the board is looking at internal and external candidates.
The resignation comes as Illumina has been locked in a monthslong heated battle with activist investor Carl Icahn, over its $7.1 billion acquisition of cancer test maker Grail that has faced regulatory hurdles. Icahn had urged shareholders to vote out its chairman, John Thompson, and deSouza. Company shareholders voted out Thompson in late May.
CFRA’s Angelo Zino joins us to unpack Meta’s Superintelligence Labs and what it means for the future of AI, innovation, and the company’s bold new direction.
AIRO CEO Joe Burns and Executive Chairman Chirinjeev Kathuria talks the future of aerospace, drones, and urban air mobility through innovation and synergy.
NYC's mayoral race heats up with a socialist candidate aiming to make the city affordable—and rattling the financial sector. Plus: Coinbase's prospects.
A stark disagreement over regulating AI in Republicans’ tax cut and spending bill is the latest tension among conservatives about whether to let states continue to put guardrails on emerging technologies or minimize such interference.
